DNA methylation profiles in ovarian cancer: Implication in diagnosis and therapy (Review)
- Authors:
- Ourania Koukoura
- Demetrios A. Spandidos
- Alexandros Daponte
- Stavros Sifakis
-
Affiliations: Department of Obstetrics and Gynecology, University Hospital of Larissa, Larissa, Thessaly, Greece, Laboratory of Clinical Virology, University of Crete Medical School, Heraklion, Crete, Greece, Department of Obstetrics and Gynecology, University Hospital of Heraklion, Heraklion, Crete, Greece - Published online on: May 8, 2014 https://doi.org/10.3892/mmr.2014.2221
- Pages: 3-9
-
Copyright: © Koukoura et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].
This article is mentioned in:
Abstract
 |
|
Hennessy BT, Coleman RL and Markman M: Ovarian cancer. Lancet. 374:1371–1382. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249. 2009. View Article : Google Scholar | |
|
Bookman MA, Brady MF, McGuire WP, et al: Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 27:1419–1425. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Claus EB, Schildkraut JM, Thompson WD and Risch NJ: The genetic attributable risk of breast and ovarian cancer. Cancer. 77:2318–2324. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Antoniou A, Pharoah PD, Narod S, et al: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 72:1117–1130. 2003. View Article : Google Scholar | |
|
Tian C, Ambrosone CB, Darcy KM, Krivak TC, Armstrong DK, Bookman MA, Davis W, Zhao H, Moysich K, Gallion H and DeLoia JA: Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol. 124:575–581. 2012. View Article : Google Scholar | |
|
Darcy KM, Brady WE, Blancato JK, Dickson RB, Hoskins WJ, McGuire WP and Birrer MJ: Prognostic relevance of c-MYC gene amplification and polysomy for chromosome 8 in suboptimally-resected, advanced stage epithelial ovarian cancers: a Gynecologic Oncology Group study. Gynecol Oncol. 114:472–479. 2009. View Article : Google Scholar | |
|
Tuefferd M, Couturier J, Penault-Llorca F, Vincent-Salomon A, Broët P, Guastalla JP, Allouache D, Combe M, Weber B, Pujade-Lauraine E and Camilleri-Broët S: HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. PLoS One. 2:e11382007. View Article : Google Scholar : PubMed/NCBI | |
|
Baylin SB and Ohm JE: Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer. 6:107–116. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Ushijima T and Asada K: Aberrant DNA methylation in contrast with mutations. Cancer Sci. 101:300–305. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Yoo CB and Jones PA: Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov. 5:37–50. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Russo VEA, Riggs AD and Martienssen RA: Epigenetic mechanisms of gene regulation. Cold Spring Harbor Laboratory Press; Plainview, NY: 1996 | |
|
Jones PA and Baylin SB: The epigenomics of cancer. Cell. 128:683–692. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Wilting RH and Dannenberg JH: Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance. Drug Resist Updat. 15:21–38. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Koukoura O, Sifakis S and Spandidos DA: DNA methylation in the human placenta and fetal growth (Review). Mol Med Rep. 5:883–839. 2012.PubMed/NCBI | |
|
Herman JG and Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 349:2042–2054. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Weber M and Schubeler D: Genomic patterns of DNA methylation: targets and function of an epigenetic mark. Curr Opin Cell Biol. 19:273–280. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Bird AP and Wolffe AP: Methylation-induced repression - belts, braces, and chromatin. Cell. 99:451–454. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Costello JF and Plass C: Methylation matters. J Med Genet. 38:285–303. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Catteau A, Harris WH, Xu CF and Solomon E: Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene. 18:1957–1965. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Esteller M: Epigenetics in cancer. N Engl J Med. 358:1148–1159. 2008. View Article : Google Scholar | |
|
Esteller M, Silva JM, Dominguez G, et al: Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst. 92:564–569. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Baylin SB and Chen WY: Aberrant gene silencing in tumor progression: implications for control of cancer. Cold Spring Harb Symp Quant Biol. 70:427–433. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Horak P, Pils D, Haller G, et al: Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer. Mol Cancer Res. 3:335–343. 2005. View Article : Google Scholar | |
|
Petrocca F, Iliopoulos D, Qin HR, et al: Alterations of the tumor suppressor gene ARLTS1 in ovarian cancer. Cancer Res. 66:10287–10291. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Yu Y, Fujii S, Yuan J, et al: Epigenetic regulation of ARHI in breast and ovarian cancer cells. Ann NY Acad Sci. 983:268–277. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Baldwin RL, Nemeth E, Tran H, et al: BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res. 60:5329–5333. 2000.PubMed/NCBI | |
|
Hilton JL, Geisler JP, Rathe JA, Hattermann-Zogg MA, DeYoung B and Buller RE: Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst. 94:1396–1406. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Li ML and Greenberg RA: Links between genome integrity and BRCA1 tumor suppression. Trends Biochem Sci. 37:418–424. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
McCoy ML, Mueller CR and Roskelley CD: The role of the breast cancer susceptibility gene 1 (BRCA1) in sporadic epithelial ovarian cancer. Reprod Biol Endocrinol. 1:722003. View Article : Google Scholar : PubMed/NCBI | |
|
Rzepecka IK, Szafron L, Stys A, et al: High frequency of allelic loss at the BRCA1 locus in ovarian cancers: clinicopathologic and molecular associations. Cancer Genet. 205:94–100. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Strathdee G, Appleton K, Illand M, et al: Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am J Pathol. 158:1121–1127. 2001. View Article : Google Scholar | |
|
Chan KY, Ozcelik H, Cheung AN, Ngan HY and Khoo US: Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer. Cancer Res. 62:4151–4156. 2002.PubMed/NCBI | |
|
Wang YQ, Yan Q, Zhang JR, Li SD, Yang YX and Wan XP: Epigenetic inactivation of BRCA1 through promoter hypermethylation in ovarian cancer progression. J Obstet Gynaecol Res. 39:549–554. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Wang C, Horiuchi A, Imai T, et al: Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene. J Pathol. 202:215–223. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Yang HJ, Liu VW, Wang Y, Tsang PC and Ngan HY: Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data. BMC Cancer. 6:2122006. View Article : Google Scholar : PubMed/NCBI | |
|
Bol GM, Suijkerbuijk KP, Bart J, Vooijs M, van der Wall E and van Diest PJ: Methylation profiles of hereditary and sporadic ovarian cancer. Histopathology. 57:363–370. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Rathi A, Virmani AK, Schorge JO, et al: Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clin Cancer Res. 8:3324–3331. 2002.PubMed/NCBI | |
|
Kontorovich T, Cohen Y, Nir U and Friedman E: Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and p53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation carriers. Breast Cancer Res Treat. 116:195–200. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Blasi MF, Ventura I, Aquilina G, et al: A human cell-based assay to evaluate the effects of alterations in the MLH1 mismatch repair gene. Cancer Res. 66:9036–9044. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Jiricny J and Nyström-Lahti M: Mismatch repair defects in cancer. Curr Opin Genet Dev. 10:157–161. 2000. View Article : Google Scholar | |
|
Kunkel TA and Erie DA: DNA mismatch repair. Annu Rev Biochem. 74:681–710. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Murphy MA and Wentzensen N: Frequency of mismatch repair deficiency in ovarian cancer: a systematic review. This article is a US Government work and, as such, is in the public domain of the United States of America. Int J Cancer. 129:1914–1922. 2011. View Article : Google Scholar | |
|
Zhang H, Zhang S, Cui J, Zhang A, Shen L and Yu H: Expression and promoter methylation status of mismatch repair gene hMLH1 and hMSH2 in epithelial ovarian cancer. Aust N Z J Obstet Gynaecol. 48:505–509. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Watanabe Y, Ueda H, Etoh T, et al: A change in promoter methylation of hMLH1 is a cause of acquired resistance to platinum-based chemotherapy in epithelial ovarian cancer. Anticancer Res. 27:1449–1452. 2007. | |
|
Barton CA, Hacker NF, Clark SJ and O’Brien PM: DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment. Gynecol Oncol. 109:129–139. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Ozdemir F, Altinisik J, Karateke A, Coksuer H and Buyru N: Methylation of tumor suppressor genes in ovarian cancer. Exp Ther Med. 4:1092–1096. 2012.PubMed/NCBI | |
|
Moselhy SS, Kumosani TA, Kamal IH, Jalal JA, Abdul Jabaar HS and Dalol A: Hypermethylation of P15, P16, and E-cadherin genes in ovarian cancer. Toxicol Ind Health. Apr 9–2013.(Epub ahead of print). | |
|
Dhillon VS, Young AR, Husain SA and Aslam M: Promoter hypermethylation of MGMT, CDH1, RAR-beta and SYK tumour suppressor genes in granulosa cell tumours (GCTs) of ovarian origin. Br J Cancer. 90:874–881. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Staub J, Chien J, Pan Y, et al: Epigenetic silencing of HSulf-1 in ovarian cancer: implications in chemoresistance. Oncogene. 26:4969–4978. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Samuel S and Naora H: Homeobox gene expression in cancer: insights from developmental regulation and deregulation. Eur J Cancer. 41:2428–2437. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Kelly ZL, Michael A, Butler-Manuel S, Pandha HS and Morgan RG: HOX genes in ovarian cancer. J Ovarian Res. 4:162011. View Article : Google Scholar | |
|
Montavon C, Gloss BS, Warton K, et al: Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer. Gynecol Oncol. 124:582–588. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Widschwendter M, Apostolidou S, Jones AA, et al: HOXA methylation in normal endometrium from premenopausal women is associated with the presence of ovarian cancer: a proof of principle study. Int J Cancer. 125:2214–2218. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Swisher EM, Gonzalez RM, Taniguchi T, et al: Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas. Mol Cancer. 8:482009. View Article : Google Scholar | |
|
Ibanez de Caceres I, Battagli C, Esteller M, et al: Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res. 64:6476–6481. 2004.PubMed/NCBI | |
|
Makarla PB, Saboorian MH, Ashfaq R, et al: Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin Cancer Res. 11:5365–5369. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Tam KF, Liu VW, Liu SS, et al: Methylation profile in benign, borderline and malignant ovarian tumors. J Cancer Res Clin Oncol. 133:331–341. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Pattamadilok J, Huapai N, Rattanatanyong P, et al: LINE-1 hypomethylation level as a potential prognostic factor for epithelial ovarian cancer. Int J Gynecol Cancer. 18:711–717. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Widschwendter M, Jiang G, Woods C, et al: DNA hypomethylation and ovarian cancer biology. Cancer Res. 64:4472–4480. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Honda H, Pazin MJ, Ji H, Wernyj RP and Morin PJ: Crucial roles of Sp1 and epigenetic modifications in the regulation of the CLDN4 promoter in ovarian cancer cells. J Biol Chem. 281:21433–21444. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Lee PS, Teaberry VS, Bland AE, et al: Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer. Int J Cancer. 126:1378–1389. 2010.PubMed/NCBI | |
|
Woloszynska-Read A, James SR, Link PA, Yu J, Odunsi K and Karpf AR: DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer. Cancer Immun. 7:212007.PubMed/NCBI | |
|
Izutsu N, Maesawa C, Shibazaki M, et al: Epigenetic modification is involved in aberrant expression of class III β-tubulin, TUBB3, in ovarian cancer cells. Int J Oncol. 32:1227–1235. 2008.PubMed/NCBI | |
|
Balch C, Matei DE, Huang TH and Nephew KP: Role of epigenomics in ovarian and endometrial cancers. Epigenomics. 2:419–447. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Strathdee G, Davies BR, Vass JK, Siddiqui N and Brown R: Cell type-specific methylation of an intronic CpG island controls expression of the MCJ gene. Carcinogenesis. 25:693–701. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Strathdee G, Vass JK, Oien KA, Siddiqui N, Curto-Garcia J and Brown R: Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy. Gynecol Oncol. 97:898–903. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Gupta A, Godwin AK, Vanderveer L, Lu A and Liu J: Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma. Cancer Res. 63:664–673. 2003.PubMed/NCBI | |
|
Teschendorff AE, Menon U, Gentry-Maharaj A, et al: An epigenetic signature in peripheral blood predicts active ovarian cancer. PLoS One. 4:e82742009. View Article : Google Scholar : PubMed/NCBI | |
|
Wei SH, Balch C, Paik HH, et al: Prognostic DNA methylation biomarkers in ovarian cancer. Clin Cancer Res. 12:2788–2794. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Wei SH, Chen CM, Strathdee G, et al: Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res. 8:2246–2252. 2002. | |
|
Zhang Q, Hu G, Yang Q, et al: A multiplex methylation-specific PCR assay for the detection of early-stage ovarian cancer using cell-free serum DNA. Gynecol Oncol. 130:132–139. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Melnikov A, Zaborina O, Dhiman N, Prabhakar BS, Chakrabarty AM and Hendrickson W: Clinical and environmental isolates of Burkholderia cepacia exhibit differential cytotoxicity towards macrophages and mast cells. Mol Microbiol. 36:1481–1493. 2000. | |
|
Ozols RF: Systemic therapy for ovarian cancer: current status and new treatments. Semin Oncol. 33:S3–S11. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Balch C, Huang TH, Brown R and Nephew KP: The epigenetics of ovarian cancer drug resistance and resensitization. Am J Obstet Gynecol. 191:1552–1572. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Su HY, Lai HC, Lin YW, et al: Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway. Int J Cancer. 127:555–567. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Nicholson LJ, Smith PR, Hiller L, et al: Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer. Int J Cancer. 125:1454–1463. 2009. View Article : Google Scholar | |
|
Strathdee G, MacKean MJ, Illand M and Brown R: A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene. 18:2335–2341. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Yap OW, Bhat G, Liu L and Tollefsbol TO: Epigenetic modifications of the estrogen receptor beta gene in epithelial ovarian cancer cells. Anticancer Res. 29:139–144. 2009.PubMed/NCBI | |
|
Lehmann U, Celikkaya G, Hasemeier B, Langer F and Kreipe H: Promoter hypermethylation of the death-associated protein kinase gene in breast cancer is associated with the invasive lobular subtype. Cancer Res. 62:6634–6638. 2002.PubMed/NCBI | |
|
Curley MD, Therrien VA, Cummings CL, et al: CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells. 27:2875–2883. 2009.PubMed/NCBI | |
|
Li M, Balch C, Montgomery JS, et al: Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med Genomics. 2:342009. View Article : Google Scholar : PubMed/NCBI | |
|
Laird PW: The power and the promise of DNA methylation markers. Nat Rev Cancer. 3:253–266. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Ivanov M, Kacevska M and Ingelman-Sundberg M: Epigenomics and interindividual differences in drug response. Clin Pharmacol Ther. 92:727–736. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Santi DV, Norment A and Garrett CE: Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc Natl Acad Sci USA. 81:6993–6997. 1984. View Article : Google Scholar : PubMed/NCBI | |
|
Kaminskas E, Farrell A, Abraham S, et al: Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res. 11:3604–3608. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Issa JP, Garcia-Manero G, Giles FJ, et al: Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 103:1635–1640. 2004.PubMed/NCBI | |
|
Issa JP, Gharibyan V, Cortes J, et al: Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol. 23:3948–3956. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Sasaki M, Kaneuchi M, Fujimoto S, Tanaka Y and Dahiya R: Hypermethylation can selectively silence multiple promoters of steroid receptors in cancers. Mol Cell Endocrinol. 202:201–207. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Takai N, Kawamata N, Walsh CS, et al: Discovery of epigenetically masked tumor suppressor genes in endometrial cancer. Mol Cancer Res. 3:261–269. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Plumb JA, Strathdee G, Sludden J, Kaye SB and Brown R: Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res. 60:6039–6044. 2000. | |
|
Fu S, Hu W, Iyer R, et al: Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer. 117:1661–1669. 2011. View Article : Google Scholar | |
|
Fang F, Balch C, Schilder J, et al: A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Cancer. 116:4043–4053. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Chen H, Hardy TM and Tollefsbol TO: Epigenomics of ovarian cancer and its chemoprevention. Front Genet. 2:672011. View Article : Google Scholar : PubMed/NCBI | |
|
Terasawa K, Sagae S, Toyota M, et al: Epigenetic inactivation of TMS1/ASC in ovarian cancer. Clin Cancer Res. 10:2000–2006. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Shi H, Wei SH, Leu YW, et al: Triple analysis of the cancer epigenome: an integrated microarray system for assessing gene expression, DNA methylation, and histone acetylation. Cancer Res. 63:2164–2171. 2003.PubMed/NCBI | |
|
Appleton K, Mackay HJ, Judson I, et al: Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol. 25:4603–4609. 2007. View Article : Google Scholar : PubMed/NCBI |
